ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.

Wang, Guanpeng; Romero, Yeni; Thevarajan, Indhujah; Zolkiewska, Anna

Wang, Guanpeng; Romero, Yeni; Thevarajan, Indhujah; Zolkiewska, Anna.

Afiliación

Wang G; Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Romero Y; Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Thevarajan I; Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Zolkiewska A; Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.

Oncoimmunology ; 12(1): 2158006, 2023.

Article en En | MEDLINE | ID: mdl-36545255

Asunto(s)

Neoplasias de la Mama Triple Negativas; Animales; Ratones; Proteína ADAM12/genética; Línea Celular Tumoral; Claudinas/metabolismo; Modelos Animales de Enfermedad; Linfocitos T; Neoplasias de la Mama Triple Negativas/tratamiento farmacológico; Neoplasias de la Mama Triple Negativas/genética; Microambiente Tumoral

Palabras clave

ADAM; B cells; CXCL12; Triple negative breast cancer; checkpoint inhibition; mesenchymal tumors; mouse models; tumor microenvironment; tumor-infiltrating immune cells

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Animals Idioma: En Revista: Oncoimmunology Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google